Increasing Age and Nonliver Comorbidities in Patients with Chronic Hepatitis B in Taiwan: A Nationwide

Cheng-Hao Tseng1,2, Yao-Chun Hsu1,2,3, Hsiu J Ho4

  • 1Division of Gastroenterology and Hepatology, E-DA Cancer Hospital/I-Shou University, Kaohsiung, Taiwan.

Insights

The chronic hepatitis B (CHB) population in Taiwan is aging, experiencing a rise in non-liver health issues and mortality. This highlights the need for enhanced monitoring and management strategies for CHB patients.

Area of Science:

  • Hepatology
  • Public Health
  • Epidemiology

Background:

  • Chronic hepatitis B (CHB) is highly prevalent in Taiwan.
  • US data indicates an aging CHB population.
  • The burden of non-liver comorbidities in Taiwanese CHB patients requires characterization.

Purpose of the Study:

  • To examine demographic shifts in Taiwan's CHB population from 2001 to 2011.
  • To assess the prevalence of non-liver comorbidities and medication use in CHB patients over a decade.
  • To compare comorbidity profiles and outcomes between CHB patients and controls.

Main Methods:

  • Retrospective analysis of the Taiwan National Health Insurance Research Database (NHIRD).
  • Inclusion of adult CHB patients diagnosed in 2001, 2006, and 2011.
  • Comparison with non-CHB controls from the Longitudinal Health Insurance Database 2000 (LHID2000).

Main Results:

  • The CHB population aged significantly, with mean age increasing from 45.4 to 52.3 years.
  • Prevalence of comorbidities (diabetes, hypertension, stroke, CKD, fractures) and medication use increased significantly.
  • CHB patients were older and had more metabolic/cardiovascular comorbidities than controls, with rising non-liver mortality.

Conclusions:

  • Taiwan's CHB population is aging, with an increasing burden of non-liver comorbidities.
  • Non-liver mortality among CHB patients has risen over the study period.
  • Findings emphasize the need for improved monitoring and management of CHB patients' non-liver health.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
101
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
110
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
95
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
111
Bioavailability: Influencing Factors01:22

Bioavailability: Influencing Factors

Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
219
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
104